Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176718 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL2757484 | 0.92 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1043580 | 0.92 | PTGES (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL571109 | 0.92 | PTGES (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL2708016 | 0.90 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL204514 | 0.90 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL14985689 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2707183 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL204876 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL13070464 | 0.88 | USP30 (0.52) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014055069-A1 | SOLID FORMS COMPRISING AN INHIBITOR OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HCRTR1 4807/4885HCRTR2 4836/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HCRTR1 4807/4885HCRTR2 4836/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HCRTR1 4807/4885HCRTR2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.